Interferons have been shown to lower low density lipoprotein (LDL) cholesterol concentrations by 20-50%. To evaluate the effect of interferons on LDL metabolic behavior in individuals with normal and mildly elevated LDL cholesterol levels, autologous LDL labeled with '"I was administered to subjects at baseline and during interferon treatment Interferon beta^^,, (IFN-ft^.,,) was administered intravenously at 4.5 x 10' units daily for at least 3 weeks before the start of kinetic study and continued for an additional 2 weeks. Results were analyzed by using a multicompartmental model that allows for two intravascular LDL compartments. In normal subjects, TFN-fi mttIM reduced LDL cholesterol and apolipoprotein (apo) B levels by 25% and 27%, respectively (p<0.05); LDL apo B synthesis was decreased by 59% (p<0.05). In hypercholesterolemic subjects, IFN-^KH,, reduced LDL cholesterol levels by 38% (p<0.05); however, apo B concentrations and production rates were not significantly decreased. Clearance of LDL from the first intravascular apo B pool was markedly reduced in these subjects, resulting in a shift in the distribution of LDL apo B from the second to the first intravascular LDL apo B pool. We conclude that interferon's actions on LDL metabolism differ in normocholesterolemic and hypercholesterolemic subjects. In normal subjects, interferon decreased LDL cholesterol and apo B levels through a reduction in the LDL apo B production rate. However, in hypercholesterolemic subjects, interferon reduced LDL cholesterol by altering the distribution of apo B mass between LDL subspecies. ( lesterol of 20% and 50% at the two doses studied, 4.5xlO 6 and 9.0 xlO 7 units, respectively. 5 Both doses were well tolerated.
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Interferons have been shown to lower low density lipoprotein (LDL) cholesterol concentrations by 20-50%. To evaluate the effect of interferons on LDL metabolic behavior in individuals with normal and mildly elevated LDL cholesterol levels, autologous LDL labeled with '"I was administered to subjects at baseline and during interferon treatment Interferon beta^^,, (IFN-ft^.,,) was administered intravenously at 4.5 x 10' units daily for at least 3 weeks before the start of kinetic study and continued for an additional 2 weeks. Results were analyzed by using a multicompartmental model that allows for two intravascular LDL compartments. In normal subjects, TFN-fi mttIM reduced LDL cholesterol and apolipoprotein (apo) B levels by 25% and 27%, respectively (p<0.05); LDL apo B synthesis was decreased by 59% (p<0.05). In hypercholesterolemic subjects, IFN-^KH,, reduced LDL cholesterol levels by 38% (p<0.05); however, apo B concentrations and production rates were not significantly decreased. Clearance of LDL from the first intravascular apo B pool was markedly reduced in these subjects, resulting in a shift in the distribution of LDL apo B from the second to the first intravascular LDL apo B pool. We conclude that interferon's actions on LDL metabolism differ in normocholesterolemic and hypercholesterolemic subjects. In normal subjects, interferon decreased LDL cholesterol and apo B levels through a reduction in the LDL apo B production rate. However, in hypercholesterolemic subjects, interferon reduced LDL cholesterol by altering the distribution of apo B mass between LDL subspecies. For example, the interferons decrease low density lipoprotein (LDL) cholesterol and apolipoprotein (apo) B levels when administered to patients with cancer. 2 -5 However, little is known about the mechanism for these effects of interferon in particular or about the general role that cytokines may play in regulating lipoprotein metabolism. Interferon beta^^,,. (IFN-ften,*) is a synthetic recombinant interferon with many of the immunomodulatory effects of the parent compound, IFN-/3. 2 However, IFN-Aero has less toxicity and is well tolerated when administered for longer periods of time. IFN-ften,,,. affects LDL concentrations in a fashion similar to other classes of interferons. When administered for 10 days to patients with stable renal cancer, daily IFN-ft^tae injections produced dose-dependent reductions in LDL cho-lesterol of 20% and 50% at the two doses studied, 4.5xlO 6 and 9.0 xlO 7 units, respectively. 5 Both doses were well tolerated.
The mechanism behind the effects of interferons in reducing LDL cholesterol and apo B concentrations is unknown. Administration of both interferon gamma and alfa inhibits hepatic and lipoprotein lipase activity, enzymes necessary for the synthesis of LDL from very low density lipoprotein (VLDL). 46 Inhibition of this pathway may result in decreased synthesis of LDL. On the other hand, interferons may act as important modulators of cellular protein synthesis by upregulating LDL receptors and enhancing LDL clearance. Because LDL synthetic and catabolic rates are abnormal in hypercholesterolemic subjects, the extent to which interferon affects LDL kinetic behavior may also depend on the presence or absence of normal lipoprotein metabolism. The effect of interferon on individuals with hypercholesterolemia has not been studied. The purpose of this study was to evaluate the effect of recombinant human IFN-fte,,,* on LDL composition and metabolism when administered to normal and mildly hypercholesterolemic subjects.
Methods

Subjects
Kinetic studies were performed before and after intravenous administration of IFM-fte^ injections to 10 subjects. Six had mild hypercholesterolemia with LDL •Percentile LDL cholesterol levels are based on lipid Research Clinics data. LDL cholesterol concentrations were determined by direct measurement of several baseline samples.
cholesterol concentrations above the 50th percentile for age and sex (LDL cholesterol levels between 160 and 185 mg/dl). All subjects were white; the mean age was 49 years (Table 1) . Two subjects were classified as having familial combined hyperlipidemia on the basis of family screening as previously described.
7 -8 Familial combined hyperlipidemia was diagnosed when at least two family members had abnormal lipid phenotypes, including at least one family member with hypertriglyceridemia and one family member with elevated triglyceride and cholesterol levels. Screening of at least three immediate relatives in the remaining four hypercholesterolemic patients did not identify a specific abnormality other than mild hypercholesterolemia; these subjects were classified as having polygenic hypercholesterolemia.
In addition, four subjects with LDL cholesterol levels below the 50th percentile (LDL cholesterol levels between 67 and 125 mg/dl) were also studied. These subjects were healthy and had no family history of hyperlipidemia or premature coronary artery disease. Subjects had normal renal, liver, and thyroid function and were receiving no medication known to affect lipoprotein metabolism.
Study Design
This research was conducted at the Clinical Research Center of the Medical College of Wisconsin. The study protocol consisted of a comparison of LDL composition and kinetic behavior in 10 subjects both with and without interferon administration. The interferon was administered to outpatients who attended the Clinical Research Center daily. Recombinant DNA-produced IFN-ftoiae was administered intravenously as a bolus injection of 4.5 x 10 6 units daily for 5 weeks. Steady-state LDL concentrations were achieved by day 21 of interferon treatment (Figure 1 ). After 21-24 days of the therapy, subjects were admitted to the Clinical Research Center for 2-3 days to initiate the kinetic study. LDL was separated from the plasma of each subject within 1 week before admission, labeled with 125 I-LDL, and then injected back into the same subject on the day of admission. Subjects were discharged from the Clinical Research Center 48 hours later and returned on a daily basis to receive the interferon injection and to have blood drawn for an additional 14 days to complete the kinetic study. Studies of LDL composition and kinetic behavior were repeated without interferon therapy. These basal studies were conducted either before or 1 month after interferon administration; subjects were allocated randomly to receive the interferon before («=5) or after (n=5) the basal turnover study. If the interferon phase of the study was performed before the basal phase, then at least 1 month separated the two portions of the study. Previous work has indicated that lipid profiles return to baseline levels within 2 weeks of discontinuation of IFN-Aenne therapy. 3 LDL prepared for injection during interferon administration was obtained after at least 2 weeks of interferon therapy; LDL prepared for injection for the basal study was obtained at least 3 weeks after interferon therapy was discontinued (for subjects whose interferon study preceded the basal study). The autologous LDL labeled for injection was collected and injected while the subject was in the same phase of the study and thus served as a tracer for the endogenous LDL pool. The entire duration of the study was 8-12 weeks.
Subjects were counseled in a step I cholesterollowering diet containing 15% protein, 55% carbohydrate, 30% fat, and <300 mg cholesterol. The initial caloric intake was calculated to maintain the subject's basal body weight during the course of the study. Body weight was carefully monitored, particularly during the interferon phase of the study when weight loss was anticipated. Diet modification to increase caloric intake was suggested if weight decreased by more than 1 kg. Diet compliance was monitored by weekly interview with the Clinical Research Center dietitian. In addition, a 3-day dietary recall was performed during the basal diet phase and also during the interferon phase. Threeday recall data were analyzed by a computer program (Nutritionist III Software, Silverton, Ore.).
The study was approved by the Clinical Research Center and the Medical College of Wisconsin human research committee, and informed consent was obtained from patients before initiation of the study.
LDL Turnover
After an overnight fast, approximately 100 ml venous blood was removed, using EDTA as an anticoagulant. Procedures were initiated within 6 hours of blood collection to separate LDL (d= 1.019-1.063 g/ml) by sequential ultracentrifugation using a Beckman model L80 ultracentrifuge. 9 The LDL fraction was then washed and concentrated by flotation through a density solution of 1.063 g/ml at 105,000g for 20 hours. The concentrated material (12-15 mg protein) was dialyzed against several changes of 0.9% saline containing 0.1% EDTA, and an aliquot was labeled with 123 I by the iodine monochloride technique of McFarlane 10 as modified for lipoproteins. 11 The iodinated material was sterilized by Millipore filtration (0.8-/im pore size), mixed with sterile albumin, and tested for pyrogenic contamination with the Limulus amoebocyte lysate (Whittaker Byproducts Inc., Walkersville, Md.). The autologous radiolabeled LDL (10-15 mg protein and 60-100 fid 123 I) was diluted in sterile saline and given intravenously as a pulse injection. Subjects were given Lugol's iodine (5 drops/day) from 3 days before to 2 weeks after injection. Blood samples were obtained 10 minutes and 1 hour after the injection, then at 2-hour intervals for the first 12 hours, and every 12 hours thereafter until they were discharged from the Clinical Research Center (48 hours after the injection). Fasting blood samples were also obtained daily for an additional 2 weeks. Urine was collected dairy in glass bottles containing sodium iodate and potassium iodide crystals. With urinary creatinine level as a guide to assess collection completeness, >90% of the urine counts were recovered. Correction for urinary losses was performed based on the daily urinary creatinine excretion.
Analysis of Samples
Sequential ultracentrifugation was used to quantitatively isolate the LDL fraction (d=1.019-1.063 g/ml) from the plasma samples obtained after injection. Radioactivity in LDL apo B was isolated by isopropanol precipitation. 12 After radioassay, the mass of the protein was determined by a modification of the Lowry procedure (Lowry et al 13 ).
Plasma Lipids and Lipoproteins
Trigh/ceride and cholesterol levels in plasma and lipoprotein fractions were determined with an enzymatic assay (reagents obtained from Boehringer Mannheim, Indianapolis, Ind.). Apo B determinations on lipoprotein fractions were performed by electroimmunoassay as described previously.
14 High density lipoprotein (HDL) cholesterol was measured after precipitation of apo B-containing lipoproteins with sodium phosphotungstate. 15 
Kinetic Model
A multicompartmental model that allows for two intravascular LDL pools (compartments [C]l and 2) and one extravascular compartment (C [3] ) was selected for analysis of kinetic data ( Figure 2 ). The synthetic input of LDL apo B appears in C(l); the LDL apo B in C(2) is derived exclusively from C(l). LDL in C(2) exchanges with the extravascular LDL pool (C [3] ). This model was derived from the kinetic model developed by Foster and coworkers (Foster et al 16 and Chait et al 17 ) , which has been shown to accurately fit LDL decay curves derived from subjects with and without significant LDL subspecies heterogeneity. We considered several potential "improvements" on this model, such as allowing direct input of LDL apo B into C(2) as well as C(l) and the addition of an extravascular compartment equilibrating with C(l) similar to the one present at C(2). However, previous efforts to incorporate these features resulted in larger error estimates for several rate constants. 16 Therefore, they were not included in our final model.
Initial conditions for modeling were established by mass-balance considerations, considering that apo B transport into C(2) must equal the transport out of C(2). Therefore,
Because the initial conditions (IC) are distributed in the same proportion as the masses (M), then
where L denotes the equilibrium rate constant between any two compartments. Because two distinct intravascular LDL pools were employed by the model, fractional clearance rates (FCRs) were determined separately for each LDL compartment. The FCR for compartment 1 (FCR^ was determined as the sum of L(13,l) and L(2,l). The FCR for compartment 2 (FCR 2 ) was defined as the sum of rate constants L(13,2) and L(0,2). Curves obtained during the basal state and during interferon administration were simultaneously fitted by this model with the CONSAM computer program. 18 For each basal and interferon kinetic study performed within an individual subject, the rate constants equilibrating the intravascular and extravascular LDL compartments, L{2,3) and L(3,2), were assumed to be unchanged. Thus, I^i^)ŵ as held equal to L(2,3)bMl, and 1X3,2)^ was held equal to LQ,!))^. All other rate constants were allowed to adjust independently. Fractional standard deviations were <25% for all rate constants. Figure 3 shows the LDL decay curves for a normolipidemic ( Figure 3a ) and hypercholesterolemic (Figure 3b ) subject and illustrates the fit of the decay curves achieved by this model for both plasma LDL and urinary radioactivity (Figures 3c and 3d) .
We also analyzed the disappearance curves by using a simpler two-compartment model, which included only one intravascular compartment in equilibrium with an extravascular compartment. 16 This model also contained a urinary iodide pool.
Statistical analysis was performed with the paired t test. Pearson's correlations were performed to test for associations between parameters.
Results
Dietary intake remained unchanged during the IFN-&";« administration. Mild decreases in caloric and fat intake were noted but were not significantly different from baseline. There was a mean nonsignificant decrease in weight of 0.6 kg during interferon treatment; no subject lost more than 2% of body weight during the 5 weeks of W^-^^ administration.
The effect of IFN-P^^^ on plasma lipid concentrations is shown in Table 2 . A significant 15% reduction of total cholesterol concentrations was observed in both normal (171 ±18 versus 145±18 mg/dl, p<0.05) and hypercholesterolemic (241 ±5 versus 197 ±3 mg/dl, /?<0.05) subjects. Modest nonsignificant increases in plasma triglyceride levels were observed in both groups; however, one subject with an elevated baseline triglyceride level (277 mg/dl) had an increase in plasma triglyceride levels to 748 mg/dl by the third week of therapy. This level returned to basal values when interferon was stopped at the conclusion of the study. HDL cholesterol levels decreased by 20% in normal subjects and by 8% in hypercholesterolemic subjects (/?=NS) during interferon therapy.
IFN-Amne produced significant reductions in LDL cholesterol of 25% in normal subjects (93±13 versus 70±14 mg/dl, p<0.05) and of 40% in hypercholesterolemic subjects (170±4 versus 104±10 mg/dl, p<0.05). However, significant decreases in LDL apo B levels were observed only in the normal group (80 ±4 versus 57±7 mg/dl, p<0.05). Among hypercholesterolemic subjects, the proportionately greater reductions of LDL cholesterol compared with LDL apo B levels resulted in a decrease in the LDL cholesterol to apo B ratio (1.2+0.1 versus 0.8+0.1, p=0.05), suggesting cholesterol depletion of the LDL particle during interferon therapy. In addition, LDL triglyceride levels were increased in hypercholesterolemic subjects receiving interferon therapy, suggesting a triglyceride enrichment of the LDL particle. However, these differences in LDL triglycerides did not achieve statistical significance because of the biological variability and small number of subjects studied. The effect of IFN-FTEH,,,. on mean LDL apo B synthesis, clearance, and rate constants is shown in Table 3 , and individual responses of LDL apo B mass, synthesis rates, and catabolic rates to interferon are shown in Table 4 . LDL production was reduced by interferon in all normocholesterolemic subjects, and the mean LDL synthetic rate fell by 46% (15.9±2.3 versus 8.6+0.8 mg/kg-day"1, p<0.05). LDL clearance from the first LDL compartment was also reduced in three of four normal subjects (mean, 1.9±0.7 versus 0.9+0.3 pools/ day,/?=NS). On the other hand, among hypercholesterolemic subjects LDL apo B mass and kinetic parameters showed greater variability in response to interferon treatment (Table 4) . LDL apo B mass decreased in four of six patients. LDL synthesis increased in two patients, decreased in one, and was essentially unchanged in the remaining three. The mean LDL synthetic rate did not change during interferon therapy. The variability in LDL apo B mass and synthetic rates could not be explained by subject characteristics such as age, gender, initial VLDL or LDL concentrations, or the presence or absence of familial combined hyperlipidemia (correlations not shown). Initial baseline LDL cholesterol level was strongly correlated with the percent change in the LDL synthetic rate during interferon treatment (r=0.66, p=0.04). Thus, initial LDL cholesterol concentrations were the best predictor of the LDL kinetic response to interferon therapy.
Days Days
During interferon treatment, all hypercholesterolemic patients had decreases in the rate constant L(2,l), which controls apo B efflux from C(l) to C(2) (mean change, 0.5±0.2 versus 0.1±0.00 pool per day,p=NS). Consequently, the LDL apo B efflux from C(l) to C(2) decreased during interferon therapy, thereby reducing the proportion of LDL apo B mass residing in the first LDL compartment (percent of total LDL apo B residing in the first LDL kinetic compartment was 54±8% versus 71 ±6%, /?<0.02). Rate constant L(2,l) was also decreased in three of four normal subjects, and these subjects also had an increased proportion of LDL partitioned in the first LDL kinetic pool during interferon treatment (41±12% versus 57±12%, />=NS). Among all subjects, the mean apo B mass in LDL pool 2 decreased because of reduced apo B flow into this compartment (l,409±232 versus 732±113 mg,p<0.02). In part because of this reduction in L(2,l), the overall clearance of apo B from C(l) (FCRj) tended to be lower during interferon treatment (1.3±0.4 versus 0.8±0.2, /7=0.09). The clearance of apo B from the second LDL compartment (FCR 2 ) was unchanged by interferon therapy in either group. The model employed to analyze LDL turnover allowed for kinetic heterogeneity between two intravascular LDL compartments. To determine if our findings could be confirmed by using a simpler model, we also analyzed our data using a model with only one intravascular and one extravascular compartment. The overall LDL synthetic rates obtained with the two-pool model correlated with those obtained from the more complex model (baseline synthetic rate, r=0.48, p=0.\6; synthetic rates during interferon therapy, r=0.66, p=0.04). During interferon therapy, LDL synthesis decreased in all four normocholesterolemic subjects (7.3 ±1.2 versus 4.5±0.4 mg/kg-day" 1 , p=0.06) while there was no change in LDL synthesis observed in hypercholesterolemic subjects (14.5±1.7 versus 13.3+1.2 mg/kg-day" 1 ,
p=0.5).
In addition, a strong correlation existed between the two models in the percent change in the LDL synthetic rate induced by interferon (r=0.86,/>=0.002). Therefore, the effect of interferon on rates of LDL synthesis derived from either model was similar. IFN-fteiiK was tolerated well. Six of the 10 subjects had mild fatigue, four had transient headaches, and three reported myalgias and flulike symptoms at therapy initiation. Three subjects had mild fever, which abated with continued administration. Acetaminophen improved symptoms in all symptomatic subjects. Transient decreases in platelet and white blood cell counts were observed in six of 10 subjects. These returned to within 20% of baseline levels in all subjects by the third week of therapy. No abnormalities of liver function were noted during the study.
Discussion
In response to interferon, distinct differences in the metabolism of LDL between normocholesterolemic and hypercholesterolemic subjects were noted. In normal subjects, IFN-ftntae significantly decreased concentrations of LDL apo B and cholesterol. This finding is similar to other reports showing reductions in LDL cholesterol and apo B levels with interferons.
2 - 5 Our results suggest that the primary mechanism for this effect was a reduction in the LDL apo B production rate. Nonsignificant reductions in the LDL FCR were also observed during this study.
Among normal subjects in this study, interferons may have acted to decrease LDL production by several possible mechanisms. First, direct inhibition of cholesterol synthesis may reduce LDL production rates. In cells derived from a Burkitt's lymphoma cell line incubated in lipoprotein-deficient medium, 3-hydroxy-3-methylglutaryl-coenzyme A (HMG CoA) reductase activity, the rate-limiting step for cholesterol synthesis, was inhibited by up to 40% in a dose-dependent manner by IFN-ft^oe. 19 Thus, interferons may act as HMG CoA reductase inhibitors. Second, interferons may also act by affecting the formation of LDL from VLDL or other precursors. Administration of IFN-a and IFN-y have been associated with an inhibition of postheparin hpase activity. 4 -6 Hepatic and lipoprotein Hpase are intravascular enzymes that are thought to be necessary for the processing of VLDL to LDL. 20 -22 A decrease in their activity may therefore be responsible for both the increased VLDL and decreased LDL levels observed in this study and could explain the decreased LDL apo B synthesis observed in normal subjects. Therefore, more than one mechanism may be operative to explain our findings.
Despite reductions in LDL cholesterol concentrations, subjects with hypercholesterolemia did not show an overall significant decrease in LDL apo B levels. Greater decreases in LDL cholesterol than LDL apo B levels produced a 24% reduction in the ratio of LDL cholesterol to apo B in this group (/>=0.05). In addition, a trend toward a triglyceride enrichment of the LDL particle was also noted. However, despite marked individual variability, no overall change was observed in the mean kinetic parameters in this group, and mean rates of LDL apo B synthesis and catabolism were not affected by interferon. Thus, our findings suggest that alterations in LDL composition that reduced the cholesterol content of LDL were the primary consequences of interferon therapy in these hypercholesterolemic subjects, rather than a direct effect on rates of LDL production or catabolism.
Analysis of the decay curves with our multicompartmental kinetic model suggested that the intravascular remodeling of LDL may be altered by interferons and therefore that I F N -/^^ has additional effects on LDL kinetic behavior separate from its alteration of LDL apo B production. IFlM-ft^^ reduced the rate constant L(2,l) in all six hypercholesterolemic subjects and in three of four normal subjects. This rate constant describes the rate of LDL apo B leaving the first LDL compartment for the second LDL pool. Because IFN-/S^rine markedly reduced L(2,l), the clearance of LDL apo B from the first LDL compartment was decreased and the flux of LDL apo B into the second LDL pool was consequently reduced. As a result, the proportion of LDL apo B residing in the first LDL compartment increased from 41% to 64% during interferon therapy (p=0.02). Therefore, the kinetic model best fit the decay data by predicting that WR-fr^ shifted the distribution of kineticalry diverse LDL subspecies. This finding was most consistent in the hypercholesterolemic subjects studied, and therefore intravascular remodeling of LDL to alter structure and/or composition may be the predominant effect of interferon in patients with underlying disorders of lipoprotein metabolism. In these subjects, LDL was more likely to become cholesterol depleted and triglyceride enriched, suggestive of interferon-induced changes in the composition and/or relative proportions of distinct LDL subspecies. Alterations in LDL composition and density have been associated with differences in binding and/or kinetic behavior of whole LDL or its individual subspecies. 23 -28 Therefore, the compositional changes induced by interferon therapy in hypercholesterolemic subjects may produce alterations in kinetic behavior of LDL subspecies similar to those predicted by our model. There are several mechanisms that are potentially responsible for the alterations in LDL composition and the observed shift in the distribution of LDL subspecies in our kinetic model. First, interferon may have decreased the transfer of cholesteryl ester from HDL to LDL or LDL precursors by inhibiting the activity of cholesterol ester transfer protein (CETP) or lecithin: cholesterol acyltransferase (LCAT). The production of cholesteryl ester-poor, triglyceride-rich LDL precursors may then enhance the formation of an LDL subspecies with these properties. In monkeys, administration of the cytokine tumor necrosis factor-a significantly reduced LCAT activity and produced cholesteryl ester-depleted, triglyceride-rich LDL. 29 CETP deficiency in humans may also result in a triglyceride-rich LDL with decreased cholesteryl ester content, 30 and therefore, WN-fi^fa may have affected the intravascular remodeling of LDL through inhibition of intravascular cholesterol ester transport. The effect of interferons or other cytokines on CETP activity has not yet been studied. In addition, interferon, by inhibiting the activity of lipoprotein lipase, could have secondary effects on the activity of CETP. Adequate activity of lipoprotein lipase enhances the ability of CETP to bind to triglyceride-rich substrates such as VLDL. 31 -34 Therefore, interferon may have multiple effects on the processing of VLDL and LDL that affect the composition and kinetic behavior of these lipoproteins. Triglyceride enrichment of LDL decreases receptor-mediated uptake, 23 perhaps because of a conformational change of the apo B particle, 24 and therefore may directly affect its catabolic fate. Thus, interferon may shift the distribution of kineticalh/ distinct LDL compartments by affecting the activity of either of these two enzymes. Finally, because LCAT and CETP activity affects VLDL composition, alterations in the activity of these enzymes may also affect LDL apo B synthesis by changing the proportion of VLDL catabolized directly by the liver. 35 Another mechanism to consider is that interferon alters the relative rates of catabolism between native LDL and oxidized LDL. When cultured human macrophages are stimulated with EFN--y and exposed to modified LDL, the activity of the scavenger LDL receptor pathway increases markedly, resulting in enhanced cellular cholesterol ester synthesis. This effect is much greater than that observed with native LDL. 36 - 37 Uptake of oxidized LDL has also been shown to suppress production of tumor necrosis factor mRNA, a cytokine that also has a great influence on lipoprotein metabolism. 38 Thus, the increased uptake of oxidized LDL by the scavenger receptor in macrophages during interferon treatment could conceivably modulate the production of other cytokines, further regulating lipoprotein metabolism and thereby having a cascade effect. Additional studies will be necessary to further evaluate these potential mechanisms.
In addition to the kinetic analysis with the threecompartment model, we analyzed our data with a two-compartment model with one intravascular and one extravascular LDL pool. Results for total LDL synthesis and catabolism were similar, suggesting that the findings were not specific to the three-compartment model. The three-compartment kinetic model chosen for analyses in this article assumes two intravascular LDL pools, with the first LDL compartment serving as the source of LDL for the second. However, the physiological and kinetic behavior of LDL is probably even more complex. Therefore, validation of our findings will require the direct measurement of the kinetic behavior of individual LDL subspecies.
The mechanism of IFN-ZSKrine's effect at reducing LDL cholesterol levels differs in normal and hypercholesterolemic subjects. In normal subjects, interferon decreased LDL production without altering LDL composition. In hypercholesterolemic subjects, interferon may act primarily to reduce LDL cholesterol content by shifting the distribution of kinetically diverse LDL subspecies. Because polygenic hypercholesterolemia and familial combined hyperlipidemia are descriptive terms that likely represent a spectrum of genetic and metabolic abnormalities, it is surprising that this group of hypercholesterolemic subjects responded to interferon differently from the normal control subjects. However, the hypercholesterolemic group may have several characteristics in common. First, dyslipidemic plasma may be more likely to have enhanced CETP activity 39 -40 and thus may have more prominent reductions in CETP activity during interferon therapy. Second, these subjects may also have higher rates of direct production of LDL 4142 and therefore may be less sensitive to interferon-induced inhibition of lipoprotein lipase-mediated processing of VLDL to LDL. Further study to better characterize the effect of interferon on lipoprotein metabolism in subjects with specific, well-defined genetic abnormalities will be necessary to fully explain the differences in LDL kinetic behavior in response to interferon observed between these two groups.
These results may have particular relevance for three reasons. First, interferon is becoming increasingly used for the treatment of chronic neoplasms and infections, such as hairy-cell leukemia 43 and non-A, non-B hepatitis, 44 - 45 and for this reason a knowledge of its effects on lipoprotein concentrations and kinetic behavior may have special relevance, particularly to those individuals who may also be at increased risk for coronary heart disease. Second, this study may shed light on the association between hypocholesterolemia and infection or chronic illness, effects that may be mediated by cytokines. 46 Third, this study demonstrates that additional information concerning LDL kinetic behavior can be derived by using a model that allows more than one intravascular compartment. In our study, use of the three-pool model suggests that interferon, an agent known to decrease LDL cholesterol concentrations, may act by affecting intravascular processing of LDL in addition to decreasing LDL production (in normal subjects). Further work will be required to correlate these effects predicted by the model with assays of CETP and LCAT activity and also with direct measurements of apo B mass in individual LDL subtractions.
We conclude that interferons affect LDL kinetic behavior by several distinct yet interrelated mechanisms. These include decreasing the synthesis and composition of LDL and affecting the distribution of LDL subspecies. The magnitude of these individual effects are further influenced by the presence and characteristics of any underlying lipoprotein disorder. Further work to better define these mechanisms is required.
